Hormone replacement therapy and cancer risk

Area of Science:

• Oncology
• Endocrinology
• Women's Health

Background:

• Hormone replacement therapy (HRT) use is associated with ongoing debate regarding its benefits and risks, particularly concerning cancer development.
• Recent research aims to clarify the complex relationship between HRT and various cancer risks.

Purpose of the Study:

• To synthesize current evidence on the association between hormone replacement therapy (HRT) and the risk of developing specific cancers.
• To evaluate the impact of different HRT components (estrogen, progestins) on cancer incidence and mortality.

Main Methods:

• Analysis of several large population studies and a prospective study investigating HRT use and cancer outcomes.
• Examination of data focusing on breast, endometrial, colon, rectal, and ovarian cancer risks in relation to HRT.

Main Results:

• A small but increased risk of breast cancer observed in HRT users, especially with combined estrogen and progesterone therapy after 5 years.
• Addition of progestins to estrogen therapy effectively prevents endometrial cancer when administered for at least 10 days monthly.
• Estrogen replacement therapy demonstrated a significant reduction in colon cancer risk, but not rectal cancer.
• A prospective study linked HRT use to increased ovarian cancer mortality.

Conclusions:

• The use of hormone replacement therapy (HRT) presents a complex risk-benefit profile concerning cancer.
• Combined estrogen and progestin therapy requires careful consideration due to potential breast cancer risks, balanced against endometrial cancer prevention.
• Estrogen therapy shows a protective effect against colon cancer, while HRT use is associated with increased ovarian cancer mortality.